High dose daunorubicin: New standard of care for FLT3 ITD mutant AML

Despite decades of use of cytarabine and anthracycline-based (7  + 3) chemotherapy as standard induction therapy for young patients with newly diagnosed AML, controversy regarding the specific anthracycline drug remains [1,2]. Is idarubicin or daunorubicin better? For which patients? At what dose? At many centers, the choice and dose of anthracycline depends upon patient age and/or institutional preference. Recently, however, the ability of clinicians to rapidly identify and delineate newly diagnosed AML patients based on specific mutational profiles has not only allowed for use of molecularly targeted agents (FLT3 and IDH1/2 inhibitors), but has also affected the choice of anthracycline.

Source: Leukemia Research - April 23, 2018 Category: Hematology Authors: Eunice S. Wang, Kristen O ’Dwyer Tags: Commentary Source Type: research